Global X Genomics & Biotechnology ETF (GNOM)
| Assets | $90.13M |
| Expense Ratio | 0.50% |
| PE Ratio | n/a |
| Shares Out | 9.12M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -21.60% |
| Volume | 62,364 |
| Open | 9.74 |
| Previous Close | 9.78 |
| Day's Range | 9.58 - 9.82 |
| 52-Week Low | 8.63 |
| 52-Week High | 13.33 |
| Beta | 1.31 |
| Holdings | 43 |
| Inception Date | Apr 5, 2019 |
About GNOM
Fund Home PageThe Global X Genomics & Biotechnology ETF (GNOM) is an exchange-traded fund that is based on the Solactive Genomics index. The fund tracks an index of global biotech equities, selected and weighted by market cap. GNOM was launched on Apr 5, 2019 and is issued by Global X.
Top 10 Holdings
47.16% of assets| Name | Symbol | Weight |
|---|---|---|
| Natera, Inc. | NTRA | 8.20% |
| CRISPR Therapeutics AG | CRSP | 5.16% |
| Moderna, Inc. | MRNA | 4.90% |
| Ultragenyx Pharmaceutical Inc. | RARE | 4.89% |
| Agilent Technologies, Inc. | A | 4.74% |
| BioMarin Pharmaceutical Inc. | BMRN | 4.02% |
| Sarepta Therapeutics, Inc. | SRPT | 3.99% |
| Illumina, Inc. | ILMN | 3.77% |
| Qiagen N.V. | QGEN | 3.76% |
| Bio-Techne Corporation | TECH | 3.73% |
News
ETF Battles: ARKG Vs IDNA Vs GNOM
Join us for a triple-header to determine the best genomics biotech ETF!
ETF Battles: ARKG Vs GNOM
Which biotech/genomics ETF is the better play?
Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up
Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4%...
Three tech subgroups can keep climbing despite the sector's record run, ETF analyst says
Investors should consider buying into genomics, cloud computing and video gaming ETFs as tech trades near records, Global X's Jay Jacobs says.
3 Genomics ETFs Worth Jumping For
The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are deliv...
This High Growth ETF May Not Be As Pricey As You Think
When it comes to growth stocks, investors often expect they will pay up to access that.